Skip to content
2000
Volume 17, Issue 1
  • ISSN: 1574-8847
  • E-ISSN: 2212-3938

Abstract

Characterized by small, highly heterogeneous patient populations, rare disease trials magnify the challenges often encountered in traditional clinical trials. In recent years, there have been increased efforts by stakeholders to improve drug development in rare diseases through novel approaches to clinical trial designs and statistical analyses. We highlight and discuss some of the current and emerging approaches aimed at overcoming challenges in rare disease clinical trials, with a focus on the ultimate stakeholder, the patient.

Loading

Article metrics loading...

/content/journals/ccp/10.2174/1574884716666210316120615
2022-03-01
2024-10-11
Loading full text...

Full text loading...

/content/journals/ccp/10.2174/1574884716666210316120615
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test